Strides Pharma Science Ltd
Report Date | Research house | Description | Reco | At Price | Target Price | UpSide /DownSide | Download |
4-Feb-21
|
Motilal Oswal
|
Slower US/Africa biz drag down earnings
|
Buy
|
887
|
980
|
10.48
|
|
30-Oct-20
|
Motilal Oswal
|
2Q – COVID-led aberration hurts performance
|
Buy
|
673
|
790
|
17.38
|
|
30-Jan-20
|
Motilal Oswal
|
Reset strategy + product-specific opportunity drive earnings
|
Buy
|
469
|
550
|
17.27
|
|
11-May-19
|
Motilal Oswal
|
Operating leverage kicks in; earnings growth set to revive
|
Buy
|
485
|
635
|
30.9
|
|
14-Mar-18
|
Motilal Oswal
|
ANDA approval momentum intact
|
Buy
|
692
|
989
|
42.9
|
|
asdsa
Upcoming Events and Recent Updates
No Recent Updates.